Menu Search
Equities

Standard BioTools Inc

FLB:FRA

Standard BioTools Inc

Actions
Health CareMedical Equipment and Services
  • Price (EUR)1.54
  • Today's Change0.04 / 2.67%
  • Shares traded45.00
  • 1 Year change-26.67%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.

  • Revenue in USD (TTM)155.90m
  • Net income in USD-170.60m
  • Incorporated2007
  • Employees534.00
  • Location
    Standard BioTools Inc2 Tower Place, Suite 2000SOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (650) 266-6000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.standardbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.